Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone levels. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys is initially developing for the treatment of patients with uncontrolled hypertension. The company has plans for the continued research and development of lorundrostat in hypertension and other potential indications. Mineralys Therapeutics was founded in 2019, and is headquartered in Radnor, Pennsylvania.

Register for Details

For more details on financing and valuation for Mineralys, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Mineralys

Forge green plus iconForge green minus icon

What is Mineralys's IPO price?

Mineralys's IPO price is $8.27 as of 1/18/24.
Forge green plus iconForge green minus icon

What is Mineralys's funding to date?

Mineralys has raised $159.18MM to date.
Forge green plus iconForge green minus icon

When was Mineralys founded?

Mineralys was founded in 2019.

Who are Mineralys's major investors?

Adams Street Partners
Ra Capital Management
Rock Springs Capital
Samsara Biocapital
RTW Investments
Andera Partners

Mineralys funding rounds and last known valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation

Series B

$118MM raised $XXX.XX $XXX.XX

Series A

$41.18MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Jul 17, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.